GSK Ariflo Long-Term Efficacy Trials Needed For COPD Approval – FDA Cmte.

GlaxoSmithKline's Ariflo needs long-term efficacy studies to confirm the PDE-4 inhibitor's maintenance of effect in chronic obstructive pulmonary disease, an FDA advisory committee agreed Sept. 5